FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12014033508311/13/14Methods of treatment and prevention of eye diseases
22014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
32014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
42014022725908/14/14Modified proteins and peptides
52014022726408/14/14Drug fusions and conjugates with extended half life
62014020560407/24/14Antigen binding constructs
72014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
82014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
92014019340707/10/14Drug fusions and conjugates
102014018775007/03/14Methods for selecting protease resistant polypeptides
112014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
122014015870406/12/14Medicament dispenser
132014014099605/22/14Anti-serum albumin biding variable domains
142014011643405/01/14Dry powder inhaler compositions
152014011292904/24/14Tumour necrosis factor receptor 1 antagonists
162014011388804/24/14Novel combination of therapeutic agents
172014011392204/24/14Compounds
182014010589404/17/14Humanized anti-il-18 antibodies
192014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
202014007631403/20/14Manifold for use in medicament dispenser
212014008086303/20/14Muscarinic acetylcholine receptor antagonists
222014005690002/27/14Method for inhibiting binding to b-cell receptor
232014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
242014005071902/20/14Antibodies
252014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
262014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
272014002359601/23/14Novel composition
282014002455801/23/14Method of treatment
292014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
302014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
312013034546512/26/13Process for the preparation of retigabine
322013033698912/19/13Methods of identifying a patient population
332013031590111/28/13Novel uses
342013031704111/28/13Compounds
352013031028111/21/13Novel antigen binding proteins
362013030233511/14/13Ligands that bind tgf-beta receptor ii
372013026771710/10/13Process for the preparation of atovaquone
382013026118510/03/13Benzamide derivatives as ep4 receptor agonists
392013025172409/26/13Antigen binding proteins to oncostatin m (osm)
402013025318809/26/13Novel compounds
412013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
422013022420408/29/13Method of treatment based on atad2 inhibitors
432013021315408/22/13Method of determining cleanliness
442013021339408/22/13Dispensing device
452013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
462013021089208/15/13Method of treatment
472013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
482013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
492013019641208/01/13Magi polynucleotides, polypetides, and antibodies
502013018925507/25/13Fusions and conjugates of insulinotropic agents
512013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
522013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
532013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
542013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
552013007819803/28/13Novel use
562013005337502/28/13Amino-quinolines as kinase inhibitors
572013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
582013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
592013003001201/31/13Compounds
602013003001501/31/13Muscarinic acetylcholine receptor antagonists
612013002354101/24/13Voltage-gated sodium channel blockers
622013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
632012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
642012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
652012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
662012028854411/15/12Novel retigabine composition
672012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
682012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
692012024074209/27/12Novel device
702012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
712012023855909/20/12Novel compounds
722012023857109/20/12Indazole derivatives as pi 3-kinase
732012023206109/13/12Novel compounds
742012020774908/16/12Dosing regimen
752012020281108/09/12Novel compounds
762012015744606/21/12Medical use
772012015749106/21/12Muscarinic acetylcholine receptor antagonists
782012015749206/21/12Antibiotic drug
792012014971106/14/12Piperidine derivatives used as orexin antagonists
802012014973106/14/12New medical use
812012012868905/24/12Anti-il-23 immunoglobulins
822012012977805/24/12Ligand that bind tgf-beta receptor rii
832012011464705/10/12Anti-serum album single variable domains
842012010013704/26/12Immunoglobulins
852012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
862012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
872012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
882012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
892012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
902012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
912012005896303/08/12Macrolides with anti-inflammatory activity
922012004625802/23/12Novel crystalline pharmaceutical product
932012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
942012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
952012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
962012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
972012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
982012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
992012000632201/12/12Drug dispenser
1002012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1012011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1022011030569212/15/11Antigen-binding contructs
1032011030569312/15/11Anitigen-binding constructs
1042011028809811/24/11Novel compounds
1052011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1062011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1072011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1082011026973811/03/11Compounds
1092011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1102011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1112011025375210/20/11Nozzle for a nasal inhaler
1122011025607410/20/11Novel use
1132011024547010/06/11Immunoglobulins
1142011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1152011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1162011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1172011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1182011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1192011015226206/23/11Novel compounds
1202011014282406/16/11Antibodies against amyloid-beta peptide
1212011014415106/16/11Novel process, salts, composition and use
1222011013569506/09/11Oral dosage form for controlled drug release
1232011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1242011011719005/19/11Pharmaceutical formulations
1252011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1262011006164603/17/11Drug dispenser
1272011006474003/17/11Antigen binding proteins
1282011006572503/17/11Triazole amide derivatives for use in therapy
1292011005916703/10/11Encapsulation of biologically active agents
1302011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1312011004502702/24/11Adjuvant
1322011004613702/24/11Pyrazole derivatives as p2x7 modulators
1332011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1342011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1352011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1362011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1372010032999612/30/10Novel combination of therapeutic agents
1382010032402212/23/10Novel compounds
1392010031657912/16/10Novel use of alkyl phosphate esters
1402010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1412010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1422010030808212/09/10Dispensing device
1432010031170612/09/10Method of treatment of allergic rhinitis
1442010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1452010030382112/02/10Immunoglobulins
1462010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1472010030512712/02/10Novel compounds
1482010030516612/02/10Novel compounds
1492010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1502010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1512010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1522010027590911/04/10Actuator for an inhaler
1532010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1542010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1552010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1562010025619910/07/10Crystalline form of an antimalarial compound
1572010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1582010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1592010022418509/09/10Actuator for an inhaler
1602010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1612010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1622010021683708/26/10Glycine transport inhibitors
1632010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1642010020325608/12/10The application of powder material to substrates
1652010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1662010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1672010019767908/05/10Compounds
1682010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1692010019076407/29/10Novel compounds
1702010018477007/22/10Compounds
1712010018499607/22/10Process of amide formation
1722010017569807/15/10Capsule
1732010017406507/08/10Compounds
1742010014809106/17/10Rapid phase luminescense spectroscopy analysis
1752010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1762010014401606/10/10Apparatus for the disruption of animal cells
1772010014475506/10/10Novel compounds
1782010014482906/10/10Novel receptor antagonists and their methods of use
1792010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1802010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1812010013735306/03/10Tricyclic compounds as antibacterials
1822010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1832010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1842010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1852010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1862010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
1872010011379605/06/10Indole derivatives as s1p1 receptor
1882010010565204/29/10Purines as cysteine protease inhibitors
1892010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
1902010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
1912010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
1922010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
1932010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
1942010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
1952010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
1962010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
1972010006816603/18/10Oral composition comprising dimethicone copolyol
1982010006940903/18/10"novel compounds"
1992010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2002010005905203/11/10Sheet driver for use in a drug dispenser
2012010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2022010005650203/04/10Compounds
2032010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2042010005659503/04/10Pyrazole derivatives as p2x7 modulators
2052010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2062010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2072010002969902/04/10Matrix metalloproteinase inhibitors
2082010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2092010001637101/21/10Indole compounds
2102010001002101/14/10Novel compounds
2112010000052801/07/10Manifold for use in medicament dispenser
2122010000052901/07/10Manifold for use in medicament dispenser
2132010000342001/07/10Medicament dispenser
2142010000423001/07/10Azatricyclic compounds and their use
2152010000424001/07/10Indole compounds
2162009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2172009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2182009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2192009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2202009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2212009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2222009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2232009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2242009029874212/03/09Process for manufacturing lactose
2252009029114611/26/09Process for manufacturing lactose
2262009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2272009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2282009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2292009027035510/29/09Compounds
2302009027051010/29/09Glycine transport inhibitors
2312009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2322009023644509/24/09Fluid dispenser
2332009023984609/24/09Novel compounds
2342009023284709/17/09Immunogenic compositions
2352009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2362009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof
2372009022157709/03/09Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
2382009021120108/27/09Apparatus and method for printing packaging elements
2392009020947208/20/09Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents
2402009020365708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2412009020367708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2422009019787108/06/09Dual pharmacophores - pde4-muscarinic antagonistics
2432009019792808/06/09Novel receptor antagonists and their methods of use
2442009018849107/30/09Medicaments
2452009018849207/30/09Canisters for use in metered dose inhalers
2462009019216007/30/09Compounds
2472009018686707/23/09Substituted diketopiperazines as oxytocin antagonists
2482009017867307/16/09Actuation indicator for a dispensing device
2492009018195007/16/09Histamine receptor antagonists comprising an azepin core


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo